NECLIFE vs NGLFINE: Stock Comparison

Nectar Lifesciences Limited vs NGL Fine-Chem Limited

Live data: 11 May 2026, 4:01 PM IST • Source: NSE and company filings

NGL Fine-Chem Limited is the larger company by market capitalisation. Nectar Lifesciences Limited shows a lower P/E and lower leverage, while NGL Fine-Chem Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Nectar Lifesciences Limited and NGL Fine-Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NECLIFE is more favourable on 3 of 12 scored metrics and NGLFINE on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NGLFINE is the larger company
₹2,015 Cr vs ₹203 Cr
P/E Ratio
NECLIFE has a lower P/E
-0.8x vs 41.23x
P/B Ratio
NECLIFE has a lower P/B
0.4x vs 6.03x
EPS
NGLFINE has higher earnings per share
₹78.04 vs ₹-8.06
Dividend Yield
NGLFINE has a higher dividend yield
0.05% vs 0%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs -3.41%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs 0%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs -21.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNECLIFENGLFINE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNECLIFENGLFINE
Live Price₹13.56₹3,260
Day Change-5.57%0.7%
Volume7 L5,953
52-Week High₹21.4₹3,329
52-Week Low₹9.3₹1,175.5
Distance from 52W High-36.64%-2.07%

Valuation

MetricNECLIFENGLFINE
Market Cap₹203 Cr₹2,015 Cr
P/E Ratio-0.8x41.23x
P/B Ratio0.4x6.03x
EPS₹-8.06₹78.04
Book Value₹42.63₹532.95
Dividend Yield0%0.05%

Growth

MetricNECLIFENGLFINE
Revenue Growth (TTM YoY)-3.41%57.2%
EPS Growth (TTM YoY)0%1,539.8%
Qtr Sales Growth-21.9%57.1%
Qtr Profit Growth-2,229%2,398%

Profitability & Leverage

MetricNECLIFENGLFINE
ROE-9.85%15.7%
ROCE-5.36%17%
Net Margin-11.28%9.59%
Operating Margin14.5%
Debt to Equity0x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricNECLIFENGLFINE
Promoter Holding51.84%72.74%
FII Holding0.5% 0.1 pp0.03% 0.03 pp
DII Holding3.74% 0.27 pp0%
Public Holding43.89% 0.37 pp27.24% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Nectar Lifesciences Limited and NGL Fine-Chem Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.